skip to content
Home

Cambridge Immunology Network

 

CIN News Subscribe to News

Read more at: World first for AI and machine learning to treat COVID-19 patients worldwide

World first for AI and machine learning to treat COVID-19 patients worldwide

15 September 2021

Addenbrooke’s Hospital in Cambridge along with 20 other hospitals from across the world and healthcare technology leader, NVIDIA, have used artificial intelligence (AI) to predict COVID-19 patients’ oxygen needs on a global scale. Read the original article here>

Read more at: Four Cambridge researchers recognised in the 2022 Breakthrough Prizes

Four Cambridge researchers recognised in the 2022 Breakthrough Prizes

10 September 2021

Four University of Cambridge researchers – Professors Shankar Balasubramanian, David Klenerman, Suchitra Sebastian and Jack Thorne – have been recognised by the Breakthrough Prize Foundation in recognition of their outstanding achievements. Read the original article here>

Read more at: Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity

Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity

6 September 2021

Findings suggest infection control measures against variants will need to continue in the post-vaccination era. The Delta variant of SARS-CoV-2, which has become the dominant variant in countries including India and the UK, has most likely spread through its ability to evade neutralising antibodies and its increased...

Read more at: Patients with SARS-CoV-2 Delta variant were more likely to be admitted to hospital compared to patients with Alpha variant

Patients with SARS-CoV-2 Delta variant were more likely to be admitted to hospital compared to patients with Alpha variant

31 August 2021

Largest study to date analysing more than 40,000 COVID-19 cases finds a two-fold increased risk of hospitalisation from delta versus alpha variant infections. Read the original article here>

Read more at: Discovery of origin of oesophageal cancer cells highlights importance of screening for pre-cancerous Barrett’s oesophagus

Discovery of origin of oesophageal cancer cells highlights importance of screening for pre-cancerous Barrett’s oesophagus

12 August 2021

Abnormal cells that develop into oesophageal cancer – cancer that affects the tube connecting the mouth and stomach – start life as cells of the stomach, according to scientists at the University of Cambridge. Read the original article here>

Read more at: The virologist helping us to stay one step ahead of infectious diseases

The virologist helping us to stay one step ahead of infectious diseases

10 August 2021

An established virologist specialising in the field of HIV drug-resistance, Ravi Gupta pivoted his expertise to address the COVID-19 pandemic. Over the last 18 months his pioneering research has helped us to stay one step ahead of emerging variants. He talks about his career as an infectious disease specialist and, in...

Read more at: Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage

Lab-grown beating heart cells identify potential drug to prevent COVID-19-related heart damage

5 August 2021

Cambridge scientists have grown beating heart cells in the lab and shown how they are vulnerable to SARS-CoV-2 infection. In a study published in Communications Biology , they used this system to show that an experimental peptide drug called DX600 can prevent the virus entering the heart cells. Read the original article...

Read more at: Rare genetic variants confer largest increase in type 2 diabetes risk seen to date

Rare genetic variants confer largest increase in type 2 diabetes risk seen to date

7 July 2021

Scientists at the University of Cambridge have identified rare genetic variants – carried by one in 3,000 people – that have a larger impact on the risk of developing type 2 diabetes than any previously identified genetic effect. Read the original article here>

Read more at: Scientists identify 160 new drugs that could be repurposed against COVID-19

Scientists identify 160 new drugs that could be repurposed against COVID-19

30 June 2021

Cambridge scientists have identified 200 approved drugs predicted to work against COVID-19 – of which only 40 are currently being tested in COVID-19 clinical trials. Read the original article here>

Read more at: Upgrading PPE for staff working on COVID-19 wards cut hospital-acquired infections dramatically

Upgrading PPE for staff working on COVID-19 wards cut hospital-acquired infections dramatically

29 June 2021

When Addenbrooke’s Hospital in Cambridge upgraded its face masks for staff working on COVID-19 wards to filtering face piece 3 (FFP3) respirators, it saw a dramatic fall – up to 100% – in hospital-acquired SARS-CoV-2 infections among these staff. Read the original article here>

Contact us

Cambridge Immunology Network Coordinator

University of Cambridge Department of Medicine,
Jeffrey Cheah Biomedical Centre,
Cambridge Biomedical Campus, Puddicombe Way,
Cambridge, CB2 0AW

Contact: webmaster@immunology.cam.ac.uk

Site Privacy & Cookie Policies

 Follow us on Twitter

Watch our webinars

Sign up to our newsletter

We are a FOCIS centre of Excellence

FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities

Read more

Study at Cambridge

About the University

Research at Cambridge